# Why a body scan leaves a separate question about muscle function

- Article ID: research-319
- Product: RETA / IGF-1 LR3 (reta-igf-1-lr3-710, reta-igf-1-lr3-711)
- Canonical page: https://heritagebiolabs.com/research-library/articles/319-why-a-body-scan-leaves-a-separate-question-about-muscle-function
- Product collection: https://heritagebiolabs.com/research-library/products/reta-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/reta-igf-1-lr3-710
- Product page: https://heritagebiolabs.com/product/reta-igf-1-lr3-711
- Reading focus: Interpreting evidence (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1997, 2025

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains connected by peptide bonds. They can act as signals by interacting with receptors. Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered form of insulin-like growth factor 1. An older retatrutide substudy used body scans to distinguish changes in fat from changes in lean tissue. Its design helps explain what evidence is missing for the named pair. [1, 2]

In that phase 2 substudy, adults with type 2 diabetes were assigned to retatrutide, dulaglutide or placebo. The main scan measure examined percentage change in total fat mass at 36 weeks. The researchers used dual-energy X-ray absorptiometry, or DXA. This technique estimates fat mass, lean soft tissue and bone-related measures. It gives a more detailed account of body composition than a scale alone. [1]

Lean mass includes more than the muscles that produce movement. It also includes water and other tissues. A change in lean mass and a change in a strength test can therefore tell different stories. The older IGF-1 LR3 literature includes experiments in animal models, such as one in pigs that measured growth and circulating hormones. Those outcomes cannot supply the missing strength measurement in adults receiving retatrutide. [1, 2]

The substudy tested retatrutide under a defined protocol, and its scans belong to those study groups. It contained no comparison with IGF-1 LR3 added. Determining whether the named pair affected muscle strength would require a study that measures function and assigns the relevant interventions. A scan can be one part of that design alongside measurements that capture what people are able to do. [1, 2]

## Sources

1. T. Coskun et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology (publication 2025-06-30). <https://pubmed.ncbi.nlm.nih.gov/40609566/>
2. V. Dunaiski et al. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. Journal of Endocrinology (publication 1997-12). <https://pubmed.ncbi.nlm.nih.gov/9488001/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 064 - RETA IGF-1 LR3.docx; article 319; content SHA-256 b234268aee88601a4486429d7c19d5209cc00bc9b321d9d77f0fee5783757d87.
